PDF(Sci-hub)
Abstract：
Matrix gla protein (MGP) is an important vitamin K-dependent inhibitor of vascular calcification. High levels of uncarboxylated, dephosphorylated MGP have been associated with vascular calcification and are responsive to vitamin K treatment. In this systematic review, we summarize the available evidence examining whether vitamin K supplementation improves surrogate measures of cardiovascular disease including artery and valve calcification, atherosclerosis and artery stiffening. Data from controlled trials of adults were obtained by searching Ovid MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and the Web of Science Core Collection. We identified nine randomized controlled trials for review, including trials of vitamin K1 or vitamin K2 supplementation, that assessed a surrogate measure of cardiovascular disease including arterial calcification, atherosclerosis or arterial stiffening. For each trial, the risk of bias was assessed applying Cochrane Collaboration methodology. The findings indicate that vitamin K does not consistently prevent progression of calcification, atherosclerosis or arterial stiffness. There may be some benefit in people with calcification at study entry. Studies were heterogenous, with relatively short follow-up and outcome measures were varied. While vitamin K supplementation clearly improves the carboxylation of dephosphoylated MGP, its role in mitigating vascular calcification is uncertain, based on current evidence.
摘要：
基质gla蛋白（MGP）是一种重要的维生素K依赖性血管钙化抑制剂。高水平的未羧化，去磷酸化的MGP与血管钙化有关，并且对维生素K治疗有反应。在这次系统审查中，我们总结了现有的证据，研究补充维生素K是否可以改善心血管疾病的替代措施，包括动脉和瓣膜钙化，动脉粥样硬化和动脉硬化。通过搜索OvidMEDLINE获得成人对照试验的数据，Embase,Cochrane中央对照试验登记册和WebofScience核心收藏。我们确定了9项随机对照试验进行综述，包括维生素K1或维生素K2补充剂的试验，评估了心血管疾病的替代措施，包括动脉钙化，动脉粥样硬化或动脉硬化。每次审判,使用Cochrane协作方法评估偏倚风险.研究结果表明，维生素K并不能持续阻止钙化的进展，动脉粥样硬化或动脉僵硬。在进入研究时钙化的人可能会有一些好处。研究是异质的，与相对较短的随访和结果测量是不同的。虽然补充维生素K可以明显改善去磷酸化MGP的羧化，它在减轻血管钙化中的作用是不确定的，根据目前的证据。
